Waldenstrom Macroglobulinemia - Pipeline Review, Q2 2011 - new market report released
Waldenstrom Macroglobulinemia - Pipeline Review, Q2 2011
The report, ´Waldenstrom Macroglobulinemia - Pipeline Review, Q2 2011´, provides an overview of the Waldenstrom Macroglobulinemia therapeutic pipeline. This report provides information on the therapeutic development for Waldenstrom Macroglobulinemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Waldenstrom Macroglobulinemia. ´Waldenstrom Macroglobulinemia - Pipeline Review, Q2 2011´ is built using data and information sourced from our proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Waldenstrom Macroglobulinemia.
- A review of the Waldenstrom Macroglobulinemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Waldenstrom Macroglobulinemia pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Waldenstrom Macroglobulinemia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Waldenstrom Macroglobulinemia pipeline depth and focus of Waldenstrom Macroglobulinemia therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Click for report details: http://www.companiesandmarkets.com/Company-Profile/waldenstrom-macroglobulinemia-pipeline-review,-q2-2011-559646.asp?prk=d791f9b406a2f5e5567b0ce7640f3950
Browse all Healthcare and Medical Market Research Reports
Browse all Healthcare and Medical Company Profile Reports
Browse all Latest Market Research Reports
Companiesandmarkets.com is a leading online business information aggregator with over 500,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles, Companiesandmarkets.comÂs online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest. Companiesandmarkets.com is focused on providing clients with exemplary customer service and a flexible approach to accessing business information. Our team have extensive expertise in the market research industry and are keen to provide clients advice on their research requirements and possible alternative sources of information; a model which provides clients a value for money solution to research.